Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma

NCT03720041 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

740

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm
DRUG: R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm
DRUG: R2: Lenalidomide plus placebo maintenance
DRUG: R2: Lenalidomide + ixazomib maintenance

Sponsor

University of Leeds

Collaborators

[object Object]
[object Object]
[object Object]